SERUM DIAGNOSIS OF MALIGNANT POTENTIAL OF ESOPHAGEAL CANCER

在食管癌患者中，癌细胞的遗传分析已被报道为评估癌细胞恶性潜能的重要工具。然而，由于蛋白质分析需要肿瘤标本和复杂的技术，一个简单的和创伤性小的方法来评估基因表达水平的临床应用是必要的。近年来，通过酶联免疫吸附试验（ELISA）检测血清中基因和蛋白质的表达水平，已成为可能。据报道，在各种癌症患者中，基因和蛋白质的表达水平都有所提高，并且是与晚期肿瘤密切相关的预后因素。因此，我们分析了340例原发性和复发性食管癌患者治疗前的血清标志物，以确定血清标志物的临床病理意义。我们发现，大多数患者血清中有高水平，而且，高血清水平与晚期肿瘤治疗反应和患者的生存有关。

In esophageal cancer patients, genetic analysis of cancer cells has been reported as an important tool to evaluate malignant potential of cancer cells. However, since protein analyzes reqiure tumor specimen and complicated techniques, a simpler and less invasive method for evaluating gene expression level is necessary for clinical application. Recently, gene & protein expression level in patients with various cancer has been made possible by measuring serum concentration with enzyme-linked immunosorbent assay (ELISA) have been reported to be raised in various cancer patients and was the prognostic factor closely associated with advanced tumor stage. We, therefore, analyzed serum markers in 340 patients with primary and recurrent esophageal cancer prior to treatment to determine the clinicopathological significance of serum markers. We found that most of the patients had high serum levels and, moreover, that high serum level was associated with advanced tumor stage treatment response and patietns' survival.